European study shows inequality in access to new medicines
Trade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US's Most-Favoured Nation (MFN) policy.
Sanofi says drug for rare disease AATD tops standard care
After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.
SCOTUS won't hear pharma's IRA complaints
The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.
MSD's Sac-TMT delivers in first phase 3 readout
MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.
Novartis reveals more data behind Pluvicto expansion bid
Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs